Reviewing Crinetics Pharmaceuticals Inc. (CRNX)’s and PDL BioPharma Inc. (NASDAQ:PDLI)’s results

This is therefore a comparing of the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation in Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and PDL BioPharma Inc. (NASDAQ:PDLI). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals Inc. 19 0.00 7.72M -1.27 0.00
PDL BioPharma Inc. 3 -3.05 96.49M -0.42 0.00

In table 1 we can see Crinetics Pharmaceuticals Inc. and PDL BioPharma Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals Inc. 41,707,185.31% -27% -20.8%
PDL BioPharma Inc. 3,312,051,625.30% -8.9% -6.7%


The Current Ratio and a Quick Ratio of Crinetics Pharmaceuticals Inc. are 18 and 18. Competitively, PDL BioPharma Inc. has 11 and 10.7 for Current and Quick Ratio. Crinetics Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than PDL BioPharma Inc.

Insider & Institutional Ownership

Institutional investors held 97.6% of Crinetics Pharmaceuticals Inc. shares and 98.5% of PDL BioPharma Inc. shares. Insiders held roughly 5.65% of Crinetics Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 0.6% of PDL BioPharma Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Crinetics Pharmaceuticals Inc. -16.58% -18.91% -21.15% -18.03% -20.72% -32.38%
PDL BioPharma Inc. -7.99% -6.19% -10% -10% 14.74% -0.69%

For the past year Crinetics Pharmaceuticals Inc. was more bearish than PDL BioPharma Inc.


On 7 of the 10 factors PDL BioPharma Inc. beats Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.